The effects of two non-steroidal anti-inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery

Yonsei Medical Journal

Volumn 56, Issue 6, 2015, Pages 1671-1677

  Jung, Ji Won ^a,b   Chung, Byung Hoon ^a   Kim, Eung Kweon ^a,c   Seo, Kyoung Yul ^a   Kim, Tae Im ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Macular edema; Miosis; Non steroidal anti inflammatory drugs; Ocular inflammation

Indexed keywords

BROMFENAC; EYE DROPS; GATIFLOXACIN; KETOROLAC; PREDNISOLONE ACETATE; STEROID; BENZOPHENONE DERIVATIVE; BROMOBENZENE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CATARACT; CATARACT EXTRACTION; CENTRAL FOVEAL SUBFIELD THICKNESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; EYE INFLAMMATION; FEMALE; HUMAN; MACULAR EDEMA; MACULAR THICKNESS; MACULAR VOLUME; MAJOR CLINICAL STUDY; MALE; MIOSIS; OCULAR SURFACE STATUS; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PUPIL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL SYSTEM PARAMETERS; INFLAMMATION; LENS IMPLANTATION; MIDDLE AGED; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREMEDICATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; BROMOBENZENES; CATARACT; CATARACT EXTRACTION; FEMALE; HUMANS; INFLAMMATION; KETOROLAC; LENS IMPLANTATION, INTRAOCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; MIOSIS; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREMEDICATION; TREATMENT OUTCOME;

EID: 84944068054     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2015.56.6.1671     Document Type: Article

References (34)

1. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229-41.
2. Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006;46:21-40.
3. Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR, et al. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology 2011;118:2120-7.
4. Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, et al. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin 2011;27:1693-703.
5. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009;3:199-210.
6. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000;11:3-6.
7. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7: 99-107.
8. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55.
9. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatmentof acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034-8.
10. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg 2007;33:1546-9.
11. Donnenfeld ED, Nichamin LD, Hardten DR, Raizman MB, Trattler W, Rajpal RK, et al. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol 2011;151:420-6.
12. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001;108:936-44.
13. Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc 2001; 99:205-10.
14. Yanai K, Huang J, Kadonosono K, Uchio E. Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol 2013;7:741-4.
15. Xu K, McDermott M, Villanueva L, Schiffman RM, Hollander DA. Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs. Clin Ophthalmol 2011;5:269-74.
16. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114: 1653-62.
17. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98(5 Suppl):741-56.
18. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007;114:881-9.
19. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146:554-60.
20. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-50.
21. Miyake K, Ogawa T, Tajika T, Gow JA, McNamara TR. Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. J Ocul Pharmacol Ther 2008;24:573-8
22. Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 1997;115:1119-22.
23. Cervantes-Coste G, Sánchez-Castro YG, Orozco-Carroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol 2009;3:219-26.
24. Russo A, Costagliola C, Delcassi L, Parmeggiani F, Romano MR, Dell’Omo R, et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm 2013;2013:476525.
25. Menke MN, Dabov S, Knecht P, Sturm V. Reproducibility of retinal thickness measurements in healthy subjects using spectralis optical coherence tomography. Am J Ophthalmol 2009;147:467-72.
26. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13.
27. Quinn CJ. Cystoid macular edema. Optom Clin 1996;5:111-30.
28. Bucci FA Jr, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008;34:1509-12.
29. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006;22:1133-40.
30. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007; 33:1539-45.
31. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, et al. Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle. Biol Pharm Bull 2000;23:1352-6.
32. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol 2004;32:180-4.
33. Epstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009;25: 415-24.
34. Kusano M, Uematsu M, Kumagami T, Sasaki H, Kitaoka T. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 2010;29:80-5.